One To Watch

Gossamer Bio

A US-based clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, underserved diseases, with a lead priority in pulmonary hypertension.

Company Overview

Gossamer Bio is a clinical-stage biopharmaceutical company advancing investigational medicines designed to address underlying disease biology in rare and high-unmet-need areas. Its flagship program is seralutinib, an inhaled small-molecule inhibitor targeting PDGFRα/β, CSF1R and c-KIT, in Phase III development for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company’s mission emphasizes improving outcomes for patients with limited treatment options.

Gossamer also maintains a broader early-stage pipeline that includes investigational programs in immunology, inflammation and oncology-relevant mechanisms, consistent with its aim to build a diversified clinical portfolio.

Headquarters and Global Presence

Gossamer Bio is headquartered in San Diego, California, with additional offices in Europe (Ireland) supporting clinical and regulatory activities. Its clinical development is executed through global trial networks, particularly in pulmonary vascular disease.

Founding and History

Founded in 2015, Gossamer Bio went public via NASDAQ and has focused its strategy on discovering, acquiring and advancing therapeutic assets with clear biological rationale. Over time, the company pivoted to center its clinical strategy on pulmonary hypertension while maintaining research initiatives across multiple therapeutic domains.

Therapy Areas and Focus

Gossamer’s disclosed priorities are:

Pulmonary arterial hypertension (PAH)
Pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Early immunology, inflammation and oncology programs through investigational molecules

The company’s focus reflects unmet needs in chronic vascular remodeling and systemic inflammatory biology, where novel mechanisms may offer differentiated benefit.

Technology Platforms and Modalities

Gossamer’s core modality work centers on orally inhaled small molecules designed for targeted delivery to disease sites.

Lead platform focus:

Seralutinib (GB002): an inhaled inhibitor of PDGFRα/β, CSF1R and c-KIT intended to disrupt key pathological drivers of pulmonary vascular remodeling.

Other early-stage assets are described as addressing inflammatory and immune pathways across conditions such as eosinophilic asthma and gastrointestinal inflammation.

Key Personnel

Faheem Hasnain, Chief Executive Officer
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Richard Aranda, Chief Medical Officer

Strategic Partnerships

Gossamer has pursued collaborative development arrangements where appropriate. Its strategic focus tends to balance internal advancement with external partnerships that can accelerate clinical execution or broaden commercialization reach, particularly for high-impact programs such as seralutinib.

FAQ Section

Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious diseases, with its leading program, seralutinib, in late-stage development for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The broader strategy includes pipeline diversification into immunology, inflammation and related areas.

The company’s primary focus is pulmonary vascular disease, especially PAH and PH-ILD. Additional clinical programs target immune and inflammatory mechanisms in other disease areas, consistent with its translational pipeline ambition.

Gossamer’s most advanced program is seralutinib, an inhaled small molecule in Phase III for PAH and PH-ILD. Other investigational assets are in earlier stages and explore inflammatory and immunology-related biology.

Seralutinib is an inhaled inhibitor designed to target PDGFRα/β, CSF1R and c-KIT pathways implicated in pulmonary vascular remodeling and disease progression. It is delivered via a dry-powder inhaler to maximize local lung exposure and minimize systemic effects.

Gossamer has progressed seralutinib into global Phase III trials, notably the PROSERA study in PAH, with topline results anticipated in 2026. Trial design includes exercise capacity endpoints and clinical worsening measures.

Key watchpoints include Phase III outcomes for seralutinib in PAH and PH-ILD, regulatory guidance on submission strategy, and differentiation versus emerging pulmonary hypertension therapies. Progress of earlier-stage programs into later development is also a strategic readthrough.

The most relevant milestones are:

Phase III seralutinib topline data in PAH (expected 2026)
Activation and progress of seralutinib trials in PH-ILD
Advancement or de-risking of early-stage immunology/inflammation assets toward registrational potential.

Want to Update your Company's Profile?